Financial Updates for the Psychedelics Industry | Page 4 of 9 | Microdose

Psychedelics News

Finance

2 Feb 2023

Irwin Naturals Secures $40 Million Financing

Irwin Naturals Secures $40 Million of Financing for its Current Operations including Psychedelic Mental Health Clinic Rollup, Potential for up to $60 Million...

By Microdose NewsDesk

Finance, Industry

3 Jan 2023

Algernon Forms Private Subsidiary to Advance DMT Stroke Program

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program...

By Microdose NewsDesk

Finance

16 Dec 2022

Gilgamesh Pharmaceuticals Raises $39 Million in Series B Financing

Gilgamesh Pharmaceuticals has announced the closing of a $39 million Series B financing....

By Jason Najum

Finance

14 Dec 2022

Mydecine Closes Sale of Mindleap for $3.6 million

Mydecine as closed a sale of their app, with PanGenomic acquiring all of Mindleap's outstanding shares for a purchase price of C$3,600,000...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Finance

13 Oct 2022

Palo Santo Closes $50 Million Psychedelic Investment Fund

Palo Santo announced the closing of its $50 million fund....

By Microdose NewsDesk

Finance

6 Oct 2022

Can Psychedelic Stocks Like MindMed and atai Ever Recover?

Should investors begin ringing the funeral bells for psychedelic stocks? Can psychedelic stocks Like MindMed and atai ever recover? James Hallifax takes a deeper look....

By James Hallifax

Finance

29 Sep 2022

PharmaTher Provides Year-End Highlights and Financials

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022...

By Microdose NewsDesk

Finance

27 Sep 2022

Breaking News: Silo Pharma Uplists to the NASDAQ

Silo Pharma on the NASDAQ? Yup, you read it right....

By Microdose NewsDesk

Finance

20 Sep 2022

Roth Capital Suspends Rating on Mydecine

As reported recently, Mydecine has been going through some volatile moments as of late....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result